A Brief History of Ideas About Platelets in Health and Disease

Platelets

Volumn , Issue , 2013, Pages

  Coller, Barry S ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882599629     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387837-3.00069-9     Document Type: Editorial

References (448)

1. Robb-Smith A.H. Why the platelets were discovered. Br J Haematol 1967, 13(4):618-637.
2. Osler W. An account of certain organisms occurring in the liquor sanguinis. Proc R Soc Lond 1874, 22:391-398.
3. Bizzozero G. Su di un nuovo elemento morfologico del sangue dei mammiferi e della sua importanza nella trombosi e nella coagulazione. L'Osservatore 1881, 17:785-787.
4. Bizzozero J. Über einen neuen Formbestandteil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung. Virchow's Archiv für pathologische Anatomie und Physiologie und für klinische Medicin 1882, 90:261-332.
5. Mazzarello P., Calligaro A.L., Calligaro A. Giulio Bizzozero: a pioneer of cell biology. Nat Rev Mol Cell Biol 2001, 2(10):776-781.
6. de G.G., Cerletti C. Platelet adhesion and aggregation and fibrin formation in flowing blood: a historical contribution by Giulio Bizzozero. Platelets 2002, 13(2):85-89.
7. Brewer D.B. Max Schultze (1865), G. Bizzozero (1882) and the discovery of the platelet. Br J Haematol 2006, 133(3):251-258.
8. Ribatti D., Crivellato E. Giulio Bizzozero and the discovery of platelets. Leuk Res 2007, 31(10):1339-1341.
9. Osler W. On certain problems in the physiology of the blood corpuscles. The Medical News 1886, 48:421-425.
10. Bizzozero G. Sul midollo delle ossa. Il Morgagni 1869.
11. Wright J.H. The origin and nature of blood plates. Boston Med Surg J 1906, 154:643-645.
12. Jones H.W., Tocantins L.M. The history of purpura hemorrhagica. Ann Med History 1933, 5:349-364.
13. Tocantins L.M. Historical notes on blood platelets. Blood 1948, 3:1073-1082.
14. Budtz-Olsen O.E. Clot Retraction 1951, Charles Thomas, Springfield.
15. Marcus A.J., Zucker M.B. The Physiology of Blood Platelets 1965, Gurne and Stratton, New York.
16. Spaet T.H. Platelets: The blood dust. Blood, Pure and Eloquent 1980, 549-571. McGraw-Hill, Inc, New York. M. Wintrobe (Ed.).
17. Brinkhous K.M. W.W. Duke and his bleeding time test. A commentary on platelet function. JAMA 1983, 250(9):1210-1214.
18. Bernard J. History of congenital hemorrhagic thrombocytopathic dystrophy. Blood Cells 1983, 9:179.
19. de Gaetano G. Historical overview of the role of platelets in hemostasis and thrombosis. Haematologica 2001, 86(4):349-356.
20. Brand A., Novotny V., Tomson B. Platelet transfusion therapy: from 1973 to 2005. Hum Immunol 2006, 67(6):413-418.
21. Kaplan C. Neonatal alloimmune thrombocytopenia: a 50-year story. Immunohematology 2007, 23(1):9-13.
22. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 2008, 111(3):981-986.
23. Coller B.S., Shattil S.J. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008, 112(8):3011-3025.
24. Kickler T.S., Dr William W. Duke: pioneer in platelet research. JAMA 2009, 301(21):2267-2269.
25. Stasi R., Newland A.C. ITP: a historical perspective. Br J Haematol 2011, 153(4):437-450.
26. Weiss H.J. The discovery of the antiplatelet effect of aspirin: a personal reminiscence. J Thromb Haemost 2003, 1(9):1869-1875.
27. Moake J.L. Defective processing of unusually large von Willebrand factor multimers and thrombotic thrombocytopenic purpura. J Thromb Haemost 2004, 2(9):1515-1521.
28. Furlan M. Proteolytic cleavage of von Willebrand factor by ADAMTS-13 prevents uninvited clumping of blood platelets. J Thromb Haemost 2004, 2(9):1505-1509.
29. Tsai H.M. A journey from sickle cell anemia to ADAMTS13. J Thromb Haemost 2004, 2(9):1510-1514.
30. Sakariassen K.S., Turitto V.T., Baumgartner H.R. Recollections of the development of flow devices for studying mechanisms of hemostasis and thrombosis in flowing whole blood. J Thromb Haemost 2004, 2(10):1681-1690.
31. Hovig T. The early discoveries of collagen-platelet interaction and studies on its role in hemostatic plug formation. J Thromb Haemost 2005, 3(1):1-6.
32. Solum N.O., Clemetson K.J. The discovery and characterization of platelet GPIb. J Thromb Haemost 2005, 3(6):1125-1132.
33. Jörgensen L. ADP-induced platelet aggregation in the microcirculation of pig myocardium and rabbit kidneys. J Thromb Haemost 2005, 3(6):1119-1124.
34. Bettex-Galland M., Clemetson K.J. First isolation of actomyosin from a non-muscle cell: first isolated platelet protein. J Thromb Haemost 2005, 3(5):834-839.
35. Bounameaux H. More on: the early discoveries of collagen-platelet interaction and studies on its role in hemostatic plug formation. J Thromb Haemost 2005, 3(5):1116.
36. Jörgensen L. The role of platelets in the initial stages of atherosclerosis. J Thromb Haemost 2006, 4(7):1443-1449.
37. Bouma B.N., van Mourik J.A. Unraveling the mystery of von Willebrand factor. J Thromb Haemost 2006, 4(3):489-495.
38. Caen J., Wu Q. Hageman factor, platelets and polyphosphates: early history and recent connection. J Thromb Haemost 2010, 8(8):1670-1674.
39. Duke W.W. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and the coagulation time and report of three cases of hemorrhagic disease relieved by transfusion. JAMA 1910, 55:1185-1192.
40. Duke W.W. The pathogenesis of purpura hemorrhagica with especial reference to the part played by blood-platelets. Arch Intern Med 1912, 10:445-469.
41. Cronkite E.P., Jacobs G.J., Brecher G., Dillard G. The hemorrhagic phase of the acute radiation syndrome due to exposure of the whole body to penetrating ionizing radiation. Am J Roentgenol Radium Ther Nuc Med 1952, 67:796-803.
42. Gardner F.H., Cohen P. The value of platelet transfusions. Med Clin North Am 1960, 44:1425-1439.
43. Cronkite E.P., Jackson D.P. The use of platelet transfusions in hemorrhagic disease. Progress in Hematology 1959, vol 2:239. Grune and Stratton, New York.
44. Platelet transfusion therapy National Institutes of Health Consensus Conference. Transfus Med Rev 1987, 1(3):195-200.
45. Schiffer C.A. Management of patients refractory to platelet transfusion--an evaluation of methods of donor selection. Prog Hematol 1987, 15:91-113.
46. Heyman M.R., Schiffer C.A. Platelet transfusion therapy for the cancer patient. Semin Oncol 1990, 17(2):198-209.
47. Slichter S.J. Platelet transfusion therapy. Hematol Oncol Clin North Am 1990, 4(1):291-311.
48. Carmen R. The selection of plastic materials for blood bags. Transfus Med Rev 1993, 7(1):1-10.
49. Murphy S. Metabolic patterns of platelets--impact on storage for transfusion. Vox Sang 1994, 67(Suppl 3):271-273.
50. Rinder H.M., Arbini A.A., Snyder E.L. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol 1999, 6(6):437-441.
51. Pamphilon D.H. The rationale and use of platelet concentrates irradiated with ultraviolet-B light. Transfus Med Rev 1999, 13(4):323-333.
52. Murphy S. The efficacy of synthetic media in the storage of human platelets for transfusion. Transfus Med Rev 1999, 13(3):153-163.
53. Roddie P.H., Turner M.L., Williamson L.M. Leucocyte depletion of blood components. Blood Rev 2000, 14(3):145-156.
54. Corash L. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes. Baillieres Best Pract Res Clin Haematol 2000, 13(4):549-563.
55. Vassallo R., Murphy Scott MD: platelet storage pioneer. Transfus Med Rev 2011, 25(2):156-161.
56. Beutler E. Platelet transfusions: the 20,000/microL trigger. Blood 1993, 81(6):1411-1413.
57. Sorensen D.K., Cronkite E.P., Bond V.P. Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia. J Clin Invest 1959, 38:1689.
58. Coller B.S., Springer K.T., Beer J.H., Mohandas N., Scudder L.E., Norton K.J., et al. Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. J Clin Invest 1992, 89:546-555.
59. Adam G., Livne A.A. Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia. Eur J Clin Invest 1992, 22:105-112.
60. Chao F.C., Kim B.K., Houranieh A.M., Liang F.H., Konrad M.W., Swisher S.N., et al. Infusible platelet membrane microvesicles: a potential transfusion substitute for platelets. Transfusion 1996, 36(6):536-542.
61. Alving B.M., Reid T.J., Fratantoni J.C., Finlayson J.S. Frozen platelets and platelet substitutes in transfusion medicine. Transfusion 1997, 37(8):866-876.
62. Alving B. Potential for synthetic phospholipids as partial platelet substitutes. Transfusion 1998, 38(11-12):997-998.
63. Kitaguchi T., Murata M., Iijima K., Kamide K., Imagawa T., Ikeda Y. Characterization of liposomes carrying von Willebrand factor-binding domain of platelet glycoprotein Ibalpha: a potential substitute for platelet transfusion. Biochem Biophys Res Commun 1999, 261(3):784-789.
64. Levi M., Friederich P.W., Middleton S., de Groot P.G., Wu Y.P., Harris R., et al. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med 1999, 5(1):107-111.
65. Blajchman M.A. Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemost 2003, 1(7):1637-1641.
66. Alving B.M. Platelet substitutes: the reality and the potential. Vox Sang 2002, 83(Suppl 1):287-288.
67. Wallace E.L., Churchill W.H., Surgenor D.M., Cho G.S., McGurk S. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion 1998, 38(7):625-636.
68. Sullivan M.T., Wallace E.L. Blood collection and transfusion in the United States in 1999. Transfusion 2005, 45(2):141-148.
69. Whitaker B.I., Green J., King M.R., Leibeg L.L., Matthew S.M., Schlumpf K.S., et al. National Blood Collection and Utilization Survey Report. United States Department of Health and Human Services 2007, 2007.
70. Fatal bacterial infections associated with platelet transfusions--United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54(7):168-70.
71. Palavecino E.L., Yomtovian R.A., Jacobs M.R. Bacterial contamination of platelets. Transfus Apher Sci 2010, 42(1):71-82.
72. Zucker M.B., Borrelli J. Reversible alterations in platelet morphology produced by anticoagulants and by cold. Blood 1954, 9(6):602-608.
73. Kattlove H.E., Alexander B. The effect of cold on platelets. I. Cold-induced platelet aggregation. Blood 1971, 38(1):39-48.
74. Peerschke E.I., Zucker M.B. Fibrinogen receptor exposure and aggregation of human blood platelets produced by ADP and chilling. Blood 1981, 57(4):663-670.
75. Filip D.J., Aster R.H. Relative hemostatic effectiveness of human platelets stored at 4 degrees and 22 degrees C. J Lab Clin Med 1978, 91(4):618-624.
76. Hoffmeister K.M. The role of lectins and glycans in platelet clearance. J Thromb Haemost 2011, 9(Suppl 1):35-43.
77. Slichter S.J., Kaufman R.M., Assmann S.F., McCullough J., Triulzi D.J., Strauss R.G., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010, 362(7):600-613.
78. Estcourt L.J., Stanworth S.J., Murphy M.F. Platelet transfusions for patients with haematological malignancies: who needs them?. Br J Haematol 2011, 154(4):425-440.
79. Rubinstein P., Carrier C., Scaradavou A., Kurtzberg J., Adamson J., Migliaccio A.R., et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998, 339(22):1565-1577.
80. Rocha V., Sanz G., Gluckman E. Umbilical cord blood transplantation. Curr Opin Hematol 2004, 11(6):375-385.
81. McKenna D.H., Brunstein C.G. Umbilical cord blood: current status and future directions. Vox Sang 2011, 100(1):150-162.
82. Brunstein C.G., Barker J.N., Weisdorf D.J., DeFor T.E., Miller J.S., Blazar B.R., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110(8):3064-3070.
83. Kuter D.J. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 2009, 60:193-206.
84. Ghanima W., Bussel J.B. Thrombopoietic agents in immune thrombocytopenia. Semin Hematol 2010, 47(3):258-265.
85. Avecilla S.T., Hattori K., Heissig B., Tejada R., Liao F., Shido K., et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004, 10(1):64-71.
86. Deutsch V., Hubel E., Kay S., Ohayon T., Katz B.Z., Many A., et al. Mimicking the haematopoietic niche microenvironment provides a novel strategy for expansion of haematopoietic and megakaryocyte-progenitor cells from cord blood. Br J Haematol 2010, 149(1):137-149.
87. Dahlberg A., Delaney C., Bernstein I.D. Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood 2011, 117(23):6083-6090.
88. Delaney C., Heimfeld S., Brashem-Stein C., Voorhies H., Manger R.L., Bernstein I.D. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010, 16(2):232-236.
89. Refaai M.A., Phipps R.P., Spinelli S.L., Blumberg N. Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. Thromb Res 2011, 127(4):287-291.
90. Refaai M.A., Fialkow L.B., Heal J.M., Henrichs K.F., Spinelli S.L., Phipps R.P., et al. An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients. Vox Sang 2011, 101(1):55-60.
91. Tokutomi K., Tagawa T., Korenaga M., Chiba M., Asai T., Watanabe N., et al. Decoration of fibrinogen gamma-chain peptide on adenosine diphosphate-encapsulated liposomes enhances binding of the liposomes to activated platelets. Int J Pharm 2011, 407(1-2):151-157.
92. Tung S.S., Parmar S., Robinson S.N., De Lima M., Shpall E.J. Ex vivo expansion of umbilical cord blood for transplantation. Best Pract Res Clin Haematol 2010, 23(2):245-257.
93. Fujimoto T.T., Kohata S., Suzuki H., Miyazaki H., Fujimura K. Production of functional platelets by differentiated embryonic stem (ES) cells in vitro. Blood 2003, 102(12):4044-4051.
94. Gaur M., Kamata T., Wang S., Moran B., Shattil S.J., Leavitt A.D. Megakaryocytes derived from human embryonic stem cells: a genetically tractable system to study megakaryocytopoiesis and integrin function. J Thromb Haemost 2006, 4(2):436-442.
95. Gekas C., Graf T. Induced pluripotent stem cell-derived human platelets: one step closer to the clinic. J Exp Med 2010, 207(13):2781-2784.
96. Kennedy M., Keller G.M. Hematopoietic commitment of ES cells in culture. Methods Enzymol 2003, 365:39-59.
97. Lu S.J., Li F., Yin H., Feng Q., Kimbrel E.A., Hahm E., et al. Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice. Cell Res 2011, 21(3):530-545.
98. Takayama N., Nishikii H., Usui J., Tsukui H., Sawaguchi A., Hiroyama T., et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 2008, 111(11):5298-5306.
99. Takayama N., Nishimura S., Nakamura S., Shimizu T., Ohnishi R., Endo H., et al. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med 2010, 207(13):2817-2830.
100. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474(7350):212-215.
101. Werlhof P.G., Wichmann J.E. Hannoverae imp fratorem Helwingiorium. Opera Medica 1775, 830:748.
102. Cole R.I. Note on the production of an agglutinating serum for blood platelets. Bull Johns Hopkins Hosp 1907, 18:261-262.
103. Ledingham J.C.G., Bedson S.P. Experimental purpura. Lancet 1916, 1:311-316.
104. Yoshida Y. Historical review. The light and shadow of Paul Kaznelson: his life and contribution to hematology. Ann Hematol 2008, 87(11):877-879.
105. Kaznelson P. Verschwinden den haemorrhagischen Diathese bei einem Fallen von essentieller Thrombopenie (Frank) nach Milz Extirpation. Splenogene thrombolitische Purpura. Wien Klin Wochenschr 1916, 29:1451-1454.
106. Harrington J., Minnich V., Hollingsworth J.W. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. Lab Clin Med 1951, 38:1-10.
107. Harrington W.J., Sprague C.C., Minnich V. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953, 38:433.
108. Louache F., Vainchenker W. Thrombocytopenia in HIV infection. Curr Opin Hematol 1994, 1(5):369-372.
109. Karpatkin S., Nardi M., Lennette E.T., Byrne B., Poiesz B. Anti-human immunodeficiency virus type 1 antibody complexes on platelets of seropositive thrombocytopenic homosexuals and narcotic addicts. Proc Natl Acad Sci U S A 1988, 85(24):9763-9767.
110. Cines D.B., Liebman H., Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009, 46(1 Suppl 2):S2-S14.
111. George J.N., Raskob G.E., Shah S.R., Rizvi M.A., Hamilton S.A., Osborne S., et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998, 129(11):886-890.
112. Warkentin T.E., Kelton J.G. Heparin and platelets. Hematol Oncol Clin North Am 1990, 4(1):243-264.
113. Warkentin T.E. HIT paradigms and paradoxes. J Thromb Haemost 2011, 9(Suppl 1):105-117.
114. Fujimura K. Helicobacter pylori infection and idiopathic thrombocytopenic purpura. Int J Hematol 2005, 81(2):113-118.
115. Jackson S., Beck P.L., Pineo G.F., Poon M.C. Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol 2005, 78(2):142-150.
116. Russo G., Miraglia V., Branciforte F., Matarese S.M., Zecca M., Bisogno G., et al. Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study. Pediatr Blood Cancer 2011, 56(2):273-278.
117. Lusher J.M., Warrier I. Use of intravenous gamma globulin in children and adolescents with idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Am J Med 1987, 83(4A):10-16.
118. Bussel J.B. The use of intravenous gamma-globulin in idiopathic thrombocytopenic purpura. Clin Immunol Immunopathol 1989, 53(2 Pt 2):S147-S155.
119. Scaradavou A., Bussel J.B. Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 1998, 35(1 Suppl 1):52-57.
120. George J.N., Woolf S.H., Raskob G.E., Wasser J.S., Aledort L.M., Ballem P.J., et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996, 88(1):3-40.
121. Cuker A., Cines D.B. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2010, 2010:377-384.
122. Kosugi S., Kurata Y., Tomiyama Y., Tahara T., Kato T., Tadokoro S., et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996, 93(3):704-706.
123. Hiyoyama K., Wada H., Shimura M., Nakasaki T., Katayama N., Nishikawa M., et al. Increased serum levels of thrombopoietin in patients with thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, or disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1997, 8(6):345-349.
124. Porcelijn L., Folman C.C., Bossers B., Huiskes E., Overbeeke M.A., Schoot C.E., et al. The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb Haemost 1998, 79(6):1101-1105.
125. Aledort L.M., Hayward C.P., Chen M.G., Nichol J.L., Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004, 76(3):205-213.
126. Krafft A., Huch R., Hartmann S., Breymann C. Combined thrombopoietin and platelet response to altitude in a patient with autoimmune thrombocytopenia. Thromb Haemost 2004, 91(3):626-627.
127. Nugent D., McMillan R., Nichol J.L., Slichter S.J. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009, 146(6):585-596.
128. Steinberg M.H., Kelton J.G., Coller B.S. Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders. N Engl J Med 1987, 317(17):1037-1042.
129. Khellaf M., Michel M., Quittet P., Viallard J.F., Alexis M., Roudot-Thoraval F., et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011.
130. Shirasugi Y., Ando K., Miyazaki K., Tomiyama Y., Okamoto S., Kurokawa M., et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol 2011, 94(1):71-80.
131. Bussel J.B., Buchanan G.R., Nugent D.J., Gnarra D.J., Bomgaars L.R., Blanchette V.S., et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011, 118(1):28-36.
132. Cheng G., Saleh M.N., Marcher C., Vasey S., Mayer B., Aivado M., et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011, 377(9763):393-402.
133. Newton-Cheh C., Hirschhorn J.N. Genetic association studies of complex traits: design and analysis issues. Mutat Res 2005, 573(1-2):54-69.
134. Carlson C.S., Eberle M.A., Kruglyak L., Nickerson D.A. Mapping complex disease loci in whole-genome association studies. Nature 2004, 429(6990):446-452.
135. Guttmacher A.E., Collins F.S. Genomic medicine--a primer. N Engl J Med 2002, 347(19):1512-1520.
136. Lander E.S. Initial impact of the sequencing of the human genome. Nature 2011, 470(7333):187-197.
137. van Loghen J.J., Dormeijer H., van der Hart M. Serological and genetical studies on a platelet antigen. Vox Sang 1959, 4:161.
138. Shulman N.R., Marder V.J., Hiler M.C. Platelet and leukocyte isoantigens and their antibodies: Serologic, physiologic, and clinical studies. Prog Hematol 1964, 4:222.
139. Shulman N.R., Aster R.H., Leitner A. Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically-controlled platelet antigen: a proposed mechanism for thrombocytopenia and its relevance in "autoimmunity.". J Clin Invest 1961, 40:1597.
140. Morrison F.S., Mollison P.L. Post-transfusion purpura. N Eng J Med 1966, 275:243-248.
141. Newman P.J., Gorski J., White G.C., Gidwitz S., Cretney C.J., Aster R.H. Enzymatic amplification of platelet-specific messenger RNA using the polymerase chain reaction. J Clin Invest 1988, 82:739-743.
142. Valentin N., Newman P.J. Human platelet alloantigens. Curr Opin Hematol 1994, 1(5):381-387.
143. Mueller-Eckhardt C., Mueller-Eckhardt G., Willen-Ohff H., Horz A., Kuenzlen E., O'Neill G.J., et al. Immunogenicity of and immune response to the human platelet antigen Zwa is strongly associated with HLA-B8 and DR3. Tissue Antigens 1985, 26(1):71-76.
144. de Waal L.P., van Dalen C.M., Engelfriet C.P., dem Borne A.E. Alloimmunization against the platelet-specific Zwa antigen, resulting in neonatal alloimmune thrombocytopenia or posttransfusion purpura, is associated with the supertypic DRw52 antigen including DR3 and DRw6. Hum Immunol 1986, 17(1):45-53.
145. L'Abbe D., Tremblay L., Filion M., Busque L., Goldman M., Decary F., et al. Alloimmunization to platelet antigen HPA-1a (PIA1) is strongly associated with both HLA-DRB3*0101 and HLA-DQB1*0201. Hum Immunol 1992, 34(2):107-114.
146. Williamson L.M., Hackett G., Rennie J., Palmer C.R., Maciver C., Hadfield R., et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 1998, 92(7):2280-2287.
147. Parry C.S., Gorski J., Stern L.J. Crystallographic structure of the human leukocyte antigen DRA, DRB3*0101: models of a directional alloimmune response and autoimmunity. J Mol Biol 2007, 371(2):435-446.
148. Guerrero J.A., Rivera J., Quiroga T., Martinez-Perez A., Anton-Garcia A.I., Martinez C., et al. Novel loci involved on platelet function and platelet count identified by a genome-wide study performed in children. Haematologica 2011, 12.
149. Di Paola J., Federici A.B., Mannucci P.M., Canciani M.T., Kritzik M., Kunicki T.J., et al. Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood 1999, 93(11):3578-3582.
150. Vijayan K.V., Goldschmidt-Clermont P.J., Roos C., Bray P.F. The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest 2000, 105(6):793-802.
151. Michelson A.D., Furman M.I., Goldschmidt-Clermont P., Mascelli M.A., Hendrix C., Coleman L., et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000, 101(9):1013-1018.
152. Beer J.H., Pederiva S., Pontiggia L. Genetics of platelet receptor single-nucleotide polymorphisms: clinical implications in thrombosis. Ann Med 2000, 32(Suppl 1):10-14.
153. Bray P.F. Platelet glycoprotein polymorphisms as risk factors for thrombosis. Curr Opin Hematol 2000, 7(5):284-289.
154. Kritzik M., Savage B., Nugent D.J., Santoso S., Ruggeri Z.M., Kunicki T.J. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood 1998, 92(7):2382-2388.
155. Vijayan K.V., Liu Y., Sun W., Ito M., Bray P.F. The Pro33 isoform of integrin beta3 enhances outside-in signaling in human platelets by regulating the activation of serine/threonine phosphatases. J Biol Chem 2005, 280(23):21756-21762.
156. Feng D., Lindpaintner K., Larson M.G., O'Donnell C.J., Lipinska I., Sutherland P.A., et al. Platelet glycoprotein IIIa Pl(a) polymorphism, fibrinogen, and platelet aggregability: the Framingham Heart Study. Circulation 2001, 104(2):140-144.
157. Vijayan K.V., Huang T.C., Liu Y., Bernardo A., Dong J.F., Goldschmidt-Clermont P.J., et al. Shear stress augments the enhanced adhesive phenotype of cells expressing the Pro33 isoform of integrin beta3. FEBS Lett 2003, 540(1-3):41-46.
158. Soranzo N., Rendon A., Gieger C., Jones C.I., Watkins N.A., Menzel S., et al. A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood 2009, 113(16):3831-3837.
159. Jones C.I., Bray S., Garner S.F., Stephens J., de B.B., Angenent W.G., et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 2009, 114(7):1405-1416.
160. Bray P.F. Platelet reactivity and genetics down on the pharm. Trans Am Clin Climatol Assoc 2006, 117:103-111.
161. Herrera-Galeano J.E., Becker D.M., Wilson A.F., Yanek L.R., Bray P., Vaidya D., et al. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol 2008, 28(8):1484-1490.
162. Cooke G.E., Liu-Stratton Y., Ferketich A.K., Moeschberger M.L., Frid D.J., Magorien R.D., et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 2006, 47(3):541-546.
163. Kunicki T.J., Nugent D.J. The genetics of normal platelet reactivity. Blood 2010, 116(15):2627-2634.
164. Ouwehand W.H. Platelet genomics and the risk of atherothrombosis. J Thromb Haemost 2007, 5(Suppl 1):188-195.
165. Cooke G.E., Bray P.F., Hamlington J.D., Pham D.M., Goldschmidt-Clermont P.J. PlA2 polymorphism and efficacy of aspirin. Lancet 1998, 351(9111):1253.
166. Szczeklik A., Undas A., Sanak M., Frolow M., Wegrzyn W. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000, 110(4):965-967.
167. Hellem A.J. The adhesiveness of human blood platelets in vitro. Scand J Clin Lab Invest 1960, 12:117.
168. Gaarder A., Jonsen J., Laland S., Hellem A.J., Owren P. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961, 192:531-532.
169. Salzman E.W., Neri L.L. Adhesiveness of blood platelets in uremia. Thromb Diath Haemorrh 1966, 15(1):84-92.
170. Bowie E.J., Owen C.A., Thompson J.H., Didisheim P. Platelet adhesiveness in von Willebrand's disease. Am J Clin Pathol 1969, 52(1):69-77.
171. Zucker M.B., Brownlea S., McPherson J. Insights into the mechanism of platelet retention in glass bead columns. Ann N Y Acad Sci 1987, 516:398-406.
172. O'Brien J.R., Heywood J.B. Some interactions between human platelets and glass: von Willebrand's disease compared with normal. J Clin Pathol 1967, 20(1):56-64.
173. Bouma B.N., Wiegerinck Y., Sixma J.J., van Mourik J.A., Mochtar I.A. Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol 1972, 236(65):104-106.
174. Coller B.S., Zucker M.B. Reversible decrease in platelet retention by glass bead columns (adhesiveness) induced by disturbing the blood. Proc Soc Exp Biol Med 1971, 136(3):769-771.
175. Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194:927-929.
176. O'Brien J. Platelet aggregation. II. Some results from a new method of study. J Clin Pathol 1962, 15:452-481.
177. Born G.V. Light on platelets. J Physiol 2005, 568(Pt 3):713-714.
178. Jørgensen L., Rowsell H.C., Hovig T., Glynn M.F., Mustard J.F. Adenosine diphosphate-induced platelet aggregation and myocardial infarction in swine. Lab Invest 1967, 17:616-644.
179. Folts J.D., Crowell E.B., Rowe G.G. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976, 54:365-370.
180. Gold H.K., Coller B.S., Yasuda T., Saito T., Fallon J.T., Guerrero J.L., et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal anti-platelet GPIIb/IIIa antibody in a dog model. Circulation 1988, 77:670-677.
181. Podesta M. Contribution a l'etude pharmacologique de thienopyridines et d'analogues furanniques. Eur J Med Chem 1974, 9(5):487-490.
182. Schomig A., Neumann F.J., Kastrati A., Schuhlen H., Blasini R., Hadamitzky M., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996, 334(17):1084-1089.
183. Balamuthusamy S., Arora R. Hematologic adverse effects of clopidogrel. Am J Ther 2007, 14(1):106-112.
184. Raju N.C., Eikelboom J.W., Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med 2008, 5(12):766-780.
185. Cattaneo M., Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999, 19(10):2281-2285.
186. Kunapuli S.P., Daniel J.L. P2 receptor subtypes in the cardiovascular system. Biochem J 1998, 336:513-523.
187. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001, 409(6817):202-207.
188. Jaremo P., Lindahl T.L., Fransson S.G., Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002, 252(3):233-238.
189. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107(23):2908-2913.
190. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109(25):3171-3175.
191. Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108(7):2244-2247.
192. Shuldiner A.R., O'Connell J.R., Bliden K.P., Gandhi A., Ryan K., Horenstein R.B., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302(8):849-857.
193. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360(4):354-362.
194. Mega J.L., Simon T., Collet J.P., Anderson J.L., Antman E.M., Bliden K., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010, 304(16):1821-1830.
195. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008, 51(14):1404-1411.
196. Bonello L., Camoin-Jau L., Armero S., Com O., Arques S., Burignat-Bonello C., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009, 103(1):5-10.
197. Wang X.D., Zhang D.F., Zhuang S.W., Lai Y. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein
198. Price M.J., Berger P.B., Teirstein P.S., Tanguay J.F., Angiolillo D.J., Spriggs D., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305(11):1097-1105.
199. Gurbel P.A., Tantry U.S. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. JAMA 2011, 305(11):1136-1137.
200. Cattaneo M. Resistance to anti-platelet agents. Thromb Res 2011, 127(Suppl 3):S61-S63.
201. Bouman H.J., Schomig E., van Werkum J.W., Velder J., Hackeng C.M., Hirschhauser C., et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011, 17(1):110-116.
202. Sibbing D., Koch W., Massberg S., Byrne R.A., Mehilli J., Schulz S., et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011, 32(13):1605-1613.
203. Trenk D., Hochholzer W., Fromm M.F., Zolk O., Valina C.M., Stratz C., et al. Paraoxonase-1 Q192R Polymorphism and Antiplatelet Effects of Clopidogrel in Patients Undergoing Elective Coronary Stent Placement. Circ Cardiovasc Genet 2011, 4(4):429-436.
204. Tomasello S.D., Tello-Montoliu A., Angiolillo D.J. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. Expert Opin Investig Drugs 2011, 20(1):119-133.
205. Paikin J.S., Eikelboom J.W., Cairns J.A., Hirsh J. New antithrombotic agents--insights from clinical trials. Nat Rev Cardiol 2010, 7(9):498-509.
206. Abergel E., Nikolsky E. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag 2010, 6:963-977.
207. Gurbel P.A., Kereiakes D.J., Tantry U.S. Ticagrelor for the treatment of arterial thrombosis. Expert Opin Pharmacother 2010, 11(13):2251-2259.
208. Oestreich J.H. Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs 2010, 11(3):340-348.
209. Douthwaite A.H., Lintott G.A.M. Gastroscopic observation of the effect of aspirin and certain other substances on the stomach. Lancet 1938, 2:1222.
210. Quick A.J. Bleeding problems in clinical medicine 1970, WB Saunders, Philadelphia.
211. Hovig T. Release of a platelet-aggregatiing substance (adenosine diphosphate) from rabbit blood platelets induced by saline "extract" of tendons. Thromb Diath Haemorrh 1963, 143:264-278.
212. Spaet T.H., Zucker M.B. Mechanism of platelet plug formation and role of adenosine diphosphate. Am J Physiol 1964, 206:1267-1274.
213. Weiss H.J., Aledort L.M. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 1967, 2(7514):495-497.
214. Zucker M.B., Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med 1968, 127(2):547-551.
215. Weiss H.J., Aledort L.M., Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968, 47(9):2169-2180.
216. O'Brien J.R. Effect of salicylates on human platelets. Lancet 1968, 1(7557):1431.
217. Evans G., Packham M.A., Nishizawa E.E., Mustard J.F., Murphy E.A. The effect of acetylsalicyclic acid on platelet function. J Exp Med 1968, 128(5):877-894.
218. Smith J.B., Willis A.L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971, 231(25):235-237.
219. Ferreira S.H., Moncada S., Vane J.R. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol 1971, 231(25):237-239.
220. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231(25):232-235.
221. Marcus A.J. The role of prostaglandins in platelet function. Prog Hematol 1979, 11:147-171.
222. Samuelsson B. From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982. Biosci Rep 1983, 3(9):791-813.
223. Craven L.L. Prevention of coronary and cerebral thrombosis. Miss Valley Med J 1956, 78(5):213-215.
224. Mann C.C., Plummer M.L. The aspirin wars: money, medicine, and 100 years of rampant competition 1971, Knopf. 1st ed.
225. Antiplatelet Trialists C. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res ) 1988, 396:320-331.
226. Barnathan E.S., Schwartz J.S., Taylor L., Laskey W.K., Kleaveland J.P., Kussmaul W.G., et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987, 76(1):125-134.
227. Collaborative overview of randomised trials of antiplatelet therapy--I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994 308(6921):81-106.
228. ISIS Collaborative Group Randomised trial of intravenous streptokinase, oral apsirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988, 2:349-360.
229. Marcus A.J. The role of lipids in platelet function: with particular reference to the arachidonic acid pathway. Journal of Lipid Research 1978, 19:793-826.
230. Marcus A.J., Safier L.B., Broekman M.J., Islam N., Fliessbach J.H., Hajjar K.A., et al. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Thromb Haemost 1995, 74:213-217.
231. Moncada S., Gryglewski R., Bunting S., Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976, 263(5579):663-665.
232. Weksler B.B., Marcus A.J., Jaffe E.A. Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci U S A 1977, 74(9):3922-3926.
233. Radomski M.W., Palmer R.M.J., Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987, 92:639-646.
234. Radomski M.W., Palmer R.M., Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987, 2(8567):1057-1058.
235. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001, 88(8):756-762.
236. Marcus A.J., Broekman M.J., Drosopoulos J.H., Islam N., Alyonycheva T.N., Safier L.B., et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 1997, 99(6):1351-1360.
237. Marcus A.J., Broekman M.J., Drosopoulos J.H., Olson K.E., Islam N., Pinsky D.J., et al. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost 2005, 31(2):234-246.
238. Rosenberg R.D., Aird W.C. Vascular-bed--specific hemostasis and hypercoagulable states. N Engl J Med 1999, 340(20):1555-1564.
239. Wojcik J.D., Van Horn D.L., Webber A.J., Johnson S.A. Mechanism whereby platelets support the endothelium. Transfusion 1969, 9(6):324-335.
240. Andre P., Denis C.V., Ware J., Saffaripour S., Hynes R.O., Ruggeri Z.M., et al. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 2000, 96(10):3322-3328.
241. Ho-Tin-Noe B., Goerge T., Wagner D.D. Platelets: guardians of tumor vasculature. Cancer Res 2009, 69(14):5623-5626.
242. Ho-Tin-Noe B., Demers M., Wagner D.D. How platelets safeguard vascular integrity. J Thromb Haemost 2011, 9(Suppl 1):56-65.
243. Sabrkhany S., Griffioen A.W., Oude Egbrink M.G. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta 2011, 1815(2):189-196.
244. Kisucka J., Butterfield C.E., Duda D.G., Eichenberger S.C., Saffaripour S., Ware J., et al. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A 2006, 103(4):855-860.
245. Nurden A.T. Platelets, inflammation and tissue regeneration. Thromb Haemostas 2011, 105(Suppl 1):S13-S33.
246. Italiano J.E., Mairuhu A.T., Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol 2010, 17(6):578-584.
247. Varon D., Shai E. Role of platelet-derived microparticles in angiogenesis and tumor progression. Discov Med 2009, 8(43):237-241.
248. The works of William Hewson. London: F.R.S. Syndenham Society; 1846.
249. Bettex-Galland M., Luscher E.F. Extraction of an actomyosin-like protein from human thrombocytes. Lancet 1959, 184:276-277.
250. Kunishima S., Saito H. Advances in the understanding of MYH9 disorders. Curr Opin Hematol 2010, 17(5):405-410.
251. Glanzmann E. Hereditäre hämmorhagische thrombasthenie. Beitr Pathologie Bluplätchen J Kinderkt 1918, 88:113.
252. Zucker M.B., Pert J.H., Hilgartner M.W. Platelet function in a patient with thrombasthenia. Blood 1966, 28:524.
253. Caen J.P., Castaldi P.A., Leclerc J.C., Inceman S., Larrieu M.J., Probst M., et al. Congenital bleeding disorders with long bleeding time and normal platelet count. I. Glanzmann's thrombasthenia. Am J Med 1966, 41:4.
254. Peerschke E.I. The platelet fibrinogen receptor. Semin Hematol 1985, 22(4):241-259.
255. Bennett J.S. The platelet-fibrinogen interaction. Platelet Membrane Glycoproteins 1985, 193. Plenum, New York. J.N. George, A.T. Nurden, D.R. Phillips (Eds.).
256. Phillips D.R., Charo I.F., Parise L.V., Fitzgerald L.A. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988, 71:831-843.
257. Plow E.F., Ginsberg M.H. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Prog Hem Thromb 1989, 9:117-156.
258. Coller B.S., Seligsohn U., Peretz H., Newman P.J. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol 1994, 31:301-311.
259. Nurden A.T., Caen J.P. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br J Haematol 1974, 28:253-260.
260. Phillips D.R., Jenkins C.S., Luscher E.F., Larrieu M. Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature 1975, 257(5527):599-600.
261. Poncz M., Eisman R., Heidenreich R., Silver S.M., Vilaire G., Surrey S., et al. Structure of the platelet membrane glycoprotein IIb. Homology to the alpha subunits of the vitronectin and fibronectin membrane receptors. J Biol Chem 1987, 262(18):8476-8482.
262. Fitzgerald L.A., Steiner B., Rall S.C., Lo S.S., Phillips D.R. Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to "integrin.". J Biol Chem 1987, 262(9):3936-3939.
263. Hynes R.O. Integrins: a family of cell surface receptors. Cell 1987, 48:549-554.
264. Coller B.S., French D.L., Mitchell B. Hereditary qualitative platelet disorders. Williams Hematology 2005, 1795-1831. McGraw-Hill, Inc, New York. 7th ed. M.A. Lichtman, B. Beutler, T.J. Kipps, U. Seligsohn, K. Kaushansky, J.T. Prchal (Eds.).
265. Hodivala-Dilke K.M., Tsakiris D.A., Rayburn H., Crowley D., Ullman-Cullere M., Ross F.P., et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999, 103(2):229-238.
266. Smyth S.S., Reis E.D., Vaananen H., Zhang W., Coller B.S. Variable protection of b3-integrin-deficient mice from thrombosis initiated by different mechanisms. Blood 2001, 98(4):1055-1062.
267. Law D.A., DeGuzmann F.R., Heiser P., Ministri-Madrid K., Phillips D.R. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 1999, 401:808-811.
268. Reynolds L.E., Conti F.J., Lucas M., Grose R., Robinson S., Stone M., et al. Accelerated re-epithelialization in beta3-integrin-deficient-mice is associated with enhanced TGF-beta1 signaling. Nat Med 2005, 11(2):167-174.
269. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002, 8(1):27-34.
270. McHugh K.P., Hodivala-Dilke K., Zheng M.H., Namba N., Lam J., Novack D., et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000, 105(4):433-440.
271. Nurden A.T., Fiore M., Nurden P., Heilig R., Pillois X. Are bone defects in rare patients with Glanzmann's thrombasthenia associated with ITGB3 or ITGA2B mutations?. Platelets 2011, 11.
272. Fang J., Hodivala-Dilke K., Johnson B.D., Du L.M., Hynes R.O., White Ii GC, et al. Therapeutic expression of the platelet-specific integrin, {alpha}IIb{beta}3, in a murine model for Glanzmann thrombasthenia. Blood 2005, 21.
273. Tronik-Le R.D., Roullot V., Poujol C., Kortulewski T., Nurden P., Marguerie G. Thrombasthenic mice generated by replacement of the integrin alpha(IIb) gene: demonstration that transcriptional activation of this megakaryocytic locus precedes lineage commitment. Blood 2000, 96(4):1399-1408.
274. Zhang J., Varas F., Stadtfeld M., Heck S., Faust N., Graf T. CD41-YFP mice allow in vivo labeling of megakaryocytic cells and reveal a subset of platelets hyperreactive to thrombin stimulation. Exp Hematol 2007, 35(3):490-499.
275. Emambokus N.R., Frampton J. The glycoprotein IIb molecule is expressed on early murine hematopoietic progenitors and regulates their numbers in sites of hematopoiesis. Immunity 2003, 19(1):33-45.
276. Massberg S., Schurzinger K., Lorenz M., Konrad I., Schulz C., Plesnila N., et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 2005, 112(8):1180-1188.
277. Wautier J.L., Gruel Y. Prenatal diagnosis of platelet disorders. Baillieres Clin Haematol 1989, 2(3):569-583.
278. Champeix P., Forestier F., Daffos F., Kaplan C. Prenatal diagnosis of a molecular variant of Glanzmann's thrombasthenia. Curr Stud Hematol Blood Transfus 1988, 55:180-183.
279. Seligsohn U., Mibashan R.S., Rodeck C.H., Nicolaides K.H., Millar D.S., Coller B.S. Prenatal diagnosis of Glanzmann's thrombasthenia. Lancet 1985, 2:1419.
280. Peretz H., Seligsohn U., Zwang E., Coller B.S., Newman P.J. Detection of the Glanzmann's thrombasthenia mutations in Arab and Iraqi-Jewish patients by polymerase chain reaction and restriction analysis of blood or urine samples. Thromb Haemostas 1991, 66:500-504.
281. Coller B.S. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb and Haemostas 2001, 86:437-443.
282. Phillips D.R., Scarborough R.M. Clinical pharmacology of eptifibatide. Am J Cardiol 1997, 80(4A):11B-20B.
283. Scarborough R.M. Development of eptifibatide. Am Heart J 1999, 138:1093-1104.
284. McClellan K.J., Goa K.L. Tirofiban. A review of its use in acute coronary syndromes. Drugs 1998, 56(6):1067-1080.
285. Chew D.P., Moliterno D.J. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol 2000, 36(7):2028-2035.
286. Bosch X., Marrugat J., Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database Syst Rev 2010, 8(9).
287. Artoni A., Li J., Mitchell B., Ruan J., Takagi J., Springer T.A., et al. Integrin b3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin aIIbb3 activation. Proc Natl Acad Sci USA 2004, 101(36):13114-13120.
288. Xiao T., Takagi J., Coller B.S., Wang J., Springer T.A. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004, 432:59-67.
289. Zhu J., Luo B.H., Xiao T., Zhang C., Nishida N., Springer T.A. Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol Cell 2008, 32(6):849-861.
290. Springer T.A., Zhu J., Xiao T. Structural basis for distinctive recognition of fibrinogen gammaC peptide by the platelet integrin alphaIIbbeta3. J Cell Biol 2008, 182(4):791-800.
291. Ye F., Kim C., Ginsberg M.H. Molecular mechanism of inside-out integrin regulation. J Thromb Haemost 2011, 9(Suppl 1):20-25.
292. Cox D. Oral GPIIb/IIIa antagonists: what went wrong?. Curr Pharm Des 2004, 10(14):1587-1596.
293. Chew D.P., Bhatt D.L., Topol E.J. Oral glycoprotein IIb/IIIa inhibitors: why don't they work?. Am J Cardiovasc Drugs 2001, 1(6):421-428.
294. Blue R., Murcia M., Karan C., Jirouskova M., Coller B.S. Application of high throughput screening to identify a novel aIIb-specific small molecule inhibitor of aIIbb3-mediated platelet Interaction with fibrinogen. Blood 2008, 111:1248-1256.
295. Blue R., Kowalska M.A., Hirsch J., Murcia M., Janczak C.A., Harrington A., et al. Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist. Blood 2009, 114(1):195-201.
296. Zhu J., Negri A., Provasi D., Filizola M., Coller B.S., Springer T.A. Closed headpiece of integrin {alpha}IIb{beta}3 and its complex with an {alpha}IIb{beta}3-specific antagonist that does not induce opening. Blood 2010, 116(23):5050-5059.
297. Bernard J., Soulier J.-P. Sur une nouvelle variete de dystrophie thrombocytaire-hemorragipare congenitale. Semin Hop Paris 1948, 24:3217.
298. Weiss H.J., Tschopp T.B., Baumgartner H.R., Sussman I.I., Johnson M.M., Egan J.J. Decreased adhesion of giant (Bernard-Soulier) platelets to subendothelium. Further implications on the role of the von Willebrand factor in hemostasis. Am J Med 1974, 57(6):920-925.
299. Howard M.A., Hutton R.A., Hardisty R.M. Hereditary giant platelet syndrome: a disorder of a new aspect of platelet function. Br Med J 1973, 2(866):586-588.
300. Bithell T.C., Parekh S.J., Strong R.R. Platelet-function studies in the Bernard-Soulier syndrome. Ann N Y Acad Sci 1972, 201:145-160.
301. Grottum K.A., Solum N.O. Congenital thrombocytopenia with giant platelets: a defect in the platelet membrane. Br J Haematol 1969, 16(3):277-290.
302. Howard M.A., Firkin B.G. Ristocetin--a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971, 26(2):362-369.
303. Howard M.A., Sawers R.J., Firkin B.G. Ristocetin: a means of differentiating von Willebrand's disease into two groups. Blood 1973, 41(5):687-690.
304. Brinkhous K.M., Barnes D.S., Potter J.Y., Read M.S. von Willebrand syndrome induced by a Bothrops venom factor: bioassay for venom coagglutinin. Proc Natl Acad Sci USA 1981, 78(5):3230-3234.
305. Weiss H.J., Hoyer L.W., Rickles F.R., Varma A., Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 1973, 52(11):2708-2716.
306. Nurden A.T., Caen J.P. Specific roles for platelet surface glycoproteins in platelet function. Nature 1975, 255(5511):720-722.
307. Clemetson K.J., McGregor J.L., James E., Dechavanne M., Lusher EF Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J Clin Invest 1982, 70:304-311.
308. Berndt M.C., Gregory C., Chong B.H., Zola H., Castaldi P.A. Additional glycoprotein defects in Bernard-Soulier's syndrome: confirmation of genetic basis by parental analysis. Blood 1983, 62(4):800-807.
309. Ruggeri Z. The platelet glycoprotein Ib-IX complex. Prog Hem Thromb 1991, 10:35-68.
310. Roth G.J. Developing relationships: arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. Blood 1991, 77:5-19.
311. Lopez J.A., Andrews R.K., Afshar-Kharghan V., Berndt M.C. Bernard-Soulier syndrome. Blood 1998, 91(12):4397-4418.
312. Coller B.S., Peerschke E.I., Scudder L.E., Sullivan C.A. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 1983, 61:99-110.
313. Montgomery R.R., Kunicki T.J., Taves C., et al. Diagnosis of Bernard-Soulier syndrome and Glanzmann's thrombasthenia with a monoclonal assay on whole blood. J Clin Invest 1983, 71:385.
314. Cauwenberghs N., Vanhoorelbeke K., Vauterin S., Westra D.F., Romo G., Huizinga E.G., et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 2001, 98(3):652-660.
315. Emsley J., Cruz M., Handin R., Liddington R. Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Biol Chem 1998, 273(17):10396-10401.
316. Vasudevan S., Roberts J.R., McClintock R.A., Dent J.A., Celikel R., Ware J., et al. Modeling and functional analysis of the interaction between von Willebrand factor A1 domain and glycoprotein Ibalpha. J Biol Chem 2000, 275(17):12763-12768.
317. Cruz M.A., Diacovo T.G., Emsley J., Liddington R., Handin R.I. Mapping the glycoprotein Ib-binding site in the von Willebrand factor A1 domain. J Biol Chem 2000, 275(25):19098-19105.
318. Springer T.A. Biology and physics of von Willebrand factor concatamers. J Thromb Haemost 2011, 9(Suppl 1):130-143.
319. Jilma-Stohlawetz P., Gorczyca M.E., Jilma B., Siller-Matula J., Gilbert J.C., Knobl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011, 105(3):545-552.
320. Ware J., Russell S., Ruggeri Z.M. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A 2000, 97(6):2803-2808.
321. Kahn M.L., Diacovo T.G., Bainton D.F., Lanza F., Trejo J., Coughlin S.R. Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and do not exhibit a Bernard-Soulier phenotype. Blood 1999, 94(12):4112-4121.
322. Ramakrishnan V., Reeves P.S., DeGuzman F., Deshpande U., Ministri-Madrid D., DuBridge R.B., et al. Increased thrombin responsiveness in platelets from mice lacking glycoprotein V. Proc Natl Acad Sci U S A 1999, 96(23):13336-13341.
323. Nieuwenhuis H.K., Sakariassen K.S., Houdijk W.P.M., Nievelstein P.F.E.M., Sixma J.J. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood 1986, 68:692-695.
324. Sixma J.J., Sakariassen K.S., Beeser-Visser N.H., Ottenhof-Rovers M., Bolhuis P.A. Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood 1984, 63(1):128-139.
325. Peterson D.M., Stathopoulos N.A., Giorgio T.D., Hellums J.D., Moake J.L. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood 1987, 69:625-628.
326. Ikeda Y., Handa M., Kawano K., Kamata T., Murata M., Araki Y., et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991, 87(4):1234-1240.
327. Kroll M.H., Hellums J.D., McIntire L.V., Schafer A.I., Moake J.L. Platelets and shear stress. Blood 1996, 88(5):1525-1541.
328. Ruggeri Z.M. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997, 78(1):611-616.
329. Wu Y.P., Vink T., Schiphorst M., van Zanten G.H., Ijsseldijk M.J., de Groot P.G., et al. Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor-glycoprotein Ib interaction and inhibited by von Willebrand factor-glycoprotein IIb/IIIa interaction. Arterioscler Thromb Vasc Biol 2000, 20(6):1661-1667.
330. Ginsburg D., Handin R.I., Bonthron D.T., Donlon T.A., Bruns G.A., Latt S.A., et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985, 228(4706):1401-1406.
331. Loscalzo J., Fisch M., Handin R.I. Solution studies of the quaternary structure and assembly of human von Willebrand factor. Biochemistry 1985, 24(16):4468-4475.
332. Weiss H.J., Hawiger J., Ruggeri Z.M., Turitto V.T., Thiagarajan P., Hoffman T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 1989, 83:288-297.
333. Pannekoek H., Voorberg J. Molecular cloning, expression and assembly of multimeric von Willebrand factor. Baillieres Clin Haematol 1989, 2(4):879-896.
334. Meyer D., Pietu G., Fressinaud E., Girma J.P. von Willebrand factor: structure and function. Mayo Clin Proc 1991, 66(5):516-523.
335. Ginsburg D. The von Willebrand factor gene and genetics of von Willebrand's disease. Mayo Clin Proc 1991, 66(5):506-515.
336. Goto S., Salomon D.R., Ikeda Y., Ruggeri Z.M. Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995, 270(40):23352-23361.
337. Zhang X., Halvorsen K., Zhang C.Z., Wong W.P., Springer T.A. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 2009, 324(5932):1330-1334.
338. Dong J.F. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005, 3(8):1710-1716.
339. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc 1924, 24:21-24.
340. Schulman I., Pierce M., Lukens A., Currimbhoy Z. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 1960, 16:943-957.
341. Upshaw J.D. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 1978, 298(24):1350-1352.
342. Levy G.G., Motto D.G., Ginsburg D. ADAMTS13 turns 3. Blood 2005, 106(1):11-17.
343. Moake J.L., Rudy C.K., Troll J.H., Weinstein M.J., Colannino N.M., Azocar J., et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982, 307(23):1432-1435.
344. Furlan M., Robles R., Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996, 87(10):4223-4234.
345. Tsai H.M., Sussman I.I., Nagel R.L. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994, 83(8):2171-2179.
346. Furlan M., Robles R., Solenthaler M., Wassmer M., Sandoz P., Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997, 89(9):3097-3103.
347. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339(22):1585-1594.
348. Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N., McGee B.M., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413(6855):488-494.
349. Moake J.L. Thrombotic thrombocytopenic purpura: survival by "giving a dam.". Trans Am Clin Climatol Assoc 2004, 115:201-219.
350. Bell W.R., Braine H.G., Ness P.M., Kickler T.S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991, 325(6):398-403.
351. Rose M., Rowe J.M., Eldor A. The changing course of thrombotic thrombocytopenic purpura and modern therapy. Blood Rev 1993, 7(2):94-103.
352. Caramazza D., Quintini G., Abbene I., Malato A., Saccullo G., Lo Coco L., et al. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion 2010, 50(12):2753-2760.
353. Balduini C.L., Gugliotta L., Luppi M., Laurenti L., Klersy C., Pieresca C., et al. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 2010, 89(6):591-596.
354. Galbusera M., Noris M., Remuzzi G. Thrombotic thrombocytopenic purpura-then and now. Semin Thromb Hemost 2006, 32(2):81-89.
355. Lopez J.A., Dong J.F. Shear stress and the role of high molecular weight von Willebrand factor multimers in thrombus formation. Blood Coagul Fibrinolysis 2005, 16(Suppl 1):S11-S16.
356. Noris P., Balduini C.L. Investigational drugs in thrombotic thrombocytopenic purpura. Expert Opin Investig Drugs 2011, 20(8):1087-1098.
357. von Willebrand E.A. Hereditar pseudoemophili. Fin Lakaresallsk Handl 1926, 68:87-112.
358. Federici A.B., Berntorp E., Lee C.A. The 80th anniversary of von Willebrand's disease: history, management and research. Haemophilia 2006, 12(6):563-572.
359. Koutts J. A short history of diagnostic tests for von Willebrand disease: in memory of Barry Firkin (1930 to 2001) and Ted Zimmerman (1937 to 1988). Semin Thromb Hemost 2006, 32(5):445-455.
360. Nilsson I.M., Blomback M., Blomback B.von Willebrand's disease in Sweden; its pathogenesis and treatment. Acta Med Scand 1959, 164:263-278.
361. Nilsson I.M., Blomback M., Jorpes E., Blomback B., Johansson S.A. Von Willebrand's disease and its correction with human plasma fraction 1-0. Acta Med Scand 1957, 159(3):179-188.
362. Goldstein A.B. Dual hemostatic defect in pseudohemophilia. J Clin Invest 1953, 32:1551.
363. Larrieu M.J., Soulier J.P. Deficiency of antihemophilic factor A in a girl associated with bleeding disorder. Rev Hematol 1953, 8(3):361-370.
364. Jurgens R., Lehmann W., Wegelius O., Eriksson A.W., Hiepler E. Antihemophilic globulin (factor VIII) deficiency in Aland (Willebrand-Jurgens) thrombopathy. Thromb Diath Haemorrh 1957, 1(2):257-260.
365. Borchgrevink C.F., Egeberg O., Godal H.C., Hjort P.F. The effect of plasma and Cohn's fraction I on the Duke and Ivy bleeding times in von Willebrand's disease. Acta Med Scand 1963, 173:235-242.
366. Owen W.G. Big piece, little piece or: yes, factor VIII is a protein. J Thromb Haemost 2005, 3(9):1905-1909.
367. Ruggeri Z.M. von Willebrand factor: looking back and looking forward. Thromb Haemost 2007, 98(1):55-62.
368. Sadler J.E. von Willebrand factor assembly and secretion. J Thromb Haemost 2009, 1:24-27.
369. Sadler J.E., Budde U., Eikenboom J.C., Favaloro E.J., Hill F.G., Holmberg L., et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006, 4(10):2103-2114.
370. Handin R.I., Wagner D.D. Molecular and cellular biology of von Willebrand factor. Prog Hemost Thromb 1989, 9:233-259.
371. Ginsburg D. Molecular genetics of von Willebrand disease. Thromb Haemost 1999, 82(2):585-591.
372. Montgomery R.R., Zimmerman T.S. von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease. J Clin Invest 1978, 61(6):1498-1507.
373. Gralnick H.R., Coller B.S., Sultan Y. Carbohydrate deficiency of the factor VIII/von Willebrand factor protein in von Willebrand's disease variants. Science 1975, 192:56-59.
374. Sadler J.E. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology Am Soc Hematol Educ Program 2009, 106-112.
375. Franchini M., Mannucci P.M. von Willebrand factor: another janus-faced hemostasis protein. Semin Thromb Hemost 2008, 34(7):663-669.
376. Lenting P.J., Vans C.J., Denis C.V. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007, 5(7):1353-1360.
377. Reilly M.P., Li M., He J., Ferguson J.F., Stylianou I.M., Mehta N.N., et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011, 377(9763):383-392.
378. Weiss H.J. von Willebrand factor and platelet function. Ann N Y Acad Sci 1991, 614:125-137.
379. Brinkhous K.M., Read M.S., Reddick R.L., Griggs T.R. Pathophysiology of platelet-aggregating von Willebrand factor: applications of the venom coagglutinin vWF assay. Ann N Y Acad Sci 1981, 370:191-204.
380. Dumas J.J., Kumar R., McDonagh T., Sullivan F., Stahl M.L., Somers W.S., et al. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J Biol Chem 2004, 279(22):23327-23334.
381. Valentijn K.M., Sadler J.E., Valentijn J.A., Voorberg J., Eikenboom J. Functional architecture of Weibel-Palade bodies. Blood 2011, 117(19):5033-5043.
382. Schneppenheim R., Budde U. von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein. J Thromb Haemost 2011, 9(Suppl 1):209-215.
383. Bounameaux H. Recherches sur le mécanisme de la rétraction du caillot et de la métamorphose visqueuse des plaquettes. Experientia 1956, 12:355.
384. Jamieson G.A. Pathophysiology of platelet thrombin receptors. Thromb Haemost 1997, 78(1):242-246.
385. Phillips D.R. Thrombin interaction with human platelets. Potentiation of thrombin-induced aggregation and release by inactivated thrombin. Thromb Diath Haemorrh 1974, 32(1):207-215.
386. Phillips D.R., Agin P.P. Platelet plasma membrane glycoproteins. Identification of a proteolytic substrate for thrombin. Biochem Biophys Res Commun 1977, 75(4):940-947.
387. Jamieson G.A., Okumura T. Reduced thrombin binding and aggregation in Bernard-Soulier platelets. J Clin Invest 1978, 61(3):861-864.
388. McGowan E.B., Ding A., Detwiler T.C. Correlation of thrombin-induced glycoprotein V hydrolysis and platelet activation. J Biol Chem 1983, 258(18):11243-11248.
389. Bienz D., Schnippering W., Clemetson K.J. Glycoprotein V is not the thrombin activation receptor on human blood platelets. Blood 1986, 68(3):720-725.
390. Vu T.K., Hung D.T., Wheaton V.I., Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991, 64(6):1057-1068.
391. Kahn M.L., Zheng Y.W., Huang W., Bigornia V., Zeng D., Moff S., et al. A dual thrombin receptor system for platelet activation. Nature 1998, 394(6694):690-694.
392. Nakanishi-Matsui M., Zheng Y.W., Sulciner D.J., Weiss E.J., Ludeman M.J., Coughlin S.R. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000, 404(6778):609-613.
393. Faruqi T.R., Weiss E.J., Shapiro M.J., Huang W., Coughlin S.R. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem 2000, 275(26):19728-19734.
394. Ramakrishnan V., DeGuzman F., Bao M., Hall S.W., Leung L.L., Phillips D.R. A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc Natl Acad Sci U S A 2001, 98(4):1823-1828.
395. De Candia E., Hall S.W., Rutella S., Landolfi R., Andrews R.K., De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 2001, 276(7):4692-4698.
396. Ruggeri Z.M., Zarpellon A., Roberts J.R., Mc Clintock R.A., Jing H., Mendolicchio G.L. Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib. Thromb Haemost 2010, 104(5):894-902.
397. Vanhoorelbeke K., Ulrichts H., Romijn R.A., Huizinga E.G., Deckmyn H. The GPIbalpha-thrombin interaction: far from crystal clear. Trends Mol Med 2004, 10(1):33-39.
398. Oestreich J. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Curr Opin Investig Drugs 2009, 10(9):988-996.
399. Vorapaxar. Am J Cardiovasc Drugs 2010, 10(6):413-418.
400. Goto S., Ogawa H., Takeuchi M., Flather M.D., Bhatt D.L. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010, 31(21):2601-2613.
401. Gasic G.J., Gasic T.B., Stewart C.C. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968, 61(1):46-52.
402. Gasic G.J. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev 1984, 3(2):99-114.
403. Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011, 11(2):123-134.
404. Greenberg J., Packham M.A., Cazenave J.P., Reimers H.J., Mustard J.F. Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest 1975, 32(4):476-484.
405. Nierodzik M.L., Klepfish A., Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995, 74(1):282-290.
406. Zacharski L.R., Rickles F.R., Henderson W.G., Martin J.F., Forman W.B., Van Eeckhout J.P., et al. Platelets and malignancy. Rationale and experimental design for the VA Cooperative Study of RA-233 in the treatment of cancer. Am J Clin Oncol 1982, 5(6):593-609.
407. Mehta P. Potential role of platelets in the pathogenesis of tumor metastasis. Blood 1984, 63(1):55-63.
408. Jurasz P., Alonso-Escolano D., Radomski M.W. Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 2004, 143(7):819-826.
409. Karpatkin S., Pearlstein E., Ambrogio C., Coller B.S. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988, 81(4):1012-1019.
410. Boucharaba A., Serre C.M., Gres S., Saulnier-Blache J.S., Bordet J.C., Guglielmi J., et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004, 114(12):1714-1725.
411. Huang Y.Q., Li J.J., Karpatkin S. Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. J Biol Chem 2000, 275(9):6462-6468.
412. Hejna M., Raderer M., Zielinski C.C. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999, 91(1):22-36.
413. Amirkhosravi A., Amaya M., Siddiqui F., Biggerstaff J.P., Meyer T.V., Francis J.L. Blockade of GPIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. Platelets 1999, 10:285-292.
414. Mohle R., Green D., Moore M.A., Nachman R.L., Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 1997, 94(2):663-668.
415. Verheul H.M., Hoekman K., Luykx-de Bakker S., Eekman C.A., Folman C.C., Broxterman H.J., et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997, 3(12 Pt 1):2187-2190.
416. Taverna D., Moher H., Crowley D., Borsig L., Varki A., Hynes R.O. Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins. Proc Natl Acad Sci USA 2004, 101(3):763-768.
417. Taverna D., Crowley D., Connolly M., Bronson R.T., Hynes R.O. A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res 2005, 65(22):10324-10329.
418. Gevaert K., Eggermont L., Demol H., Vandekerckhove J. A fast and convenient MALDI-MS based proteomic approach: identification of components scaffolded by the actin cytoskeleton of activated human thrombocytes. J Biotechnol 2000, 78(3):259-269.
419. Marcus K., Immler D., Sternberger J., Meyer H.E. Identification of platelet proteins separated by two-dimensional gel electrophoresis and analyzed by matrix assisted laser desorption/ionization-time of flight-mass spectrometry and detection of tyrosine-phosphorylated proteins. Electrophoresis 2000, 21(13):2622-2636.
420. Gravel P., Sanchez J.C., Walzer C., Golaz O., Hochstrasser D.F., Balant L.P., et al. Human blood platelet protein map established by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 1995, 16(7):1152-1159.
421. Asakawa J., Neel J.V., Takahashi N., Satoh C., Kaneoka S., Nishikori E., et al. Heterozygosity and ethnic variation in Japanese platelet proteins. Hum Genet 1988, 78(1):1-8.
422. Maguire P.B., Foy M., Fitzgerald D.J. Using proteomics to identify potential therapeutic targets in platelets. Biochem Soc Trans 2005, 33(Pt 2):409-412.
423. Garcia A., Watson S.P., Dwek R.A., Zitzmann N. Applying proteomics technology to platelet research. Mass Spectrom Rev 2004.
424. Perrotta P.L., Bahou W.F. Proteomics in platelet science. Curr Hematol Rep 2004, 3(6):462-469.
425. Marcus K., Meyer H.E. Two-dimensional polyacrylamide gel electrophoresis for platelet proteomics. Methods Mol Biol 2004, 273:421-434.
426. Wilcox D.A., Olsen J.C., Ishizawa L., Bray P.F., French D.L., Steeber D.A., et al. Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood 2000, 95(12):3645-3651.
427. Fang J., Jensen E.S., Boudreaux M.K., Du L.M., Hawkins T.B., Koukouritaki S.B., et al. Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci USA 2011, 108(23):9583-9588.
428. de L.A., Doazan J.P., Lemesle G., Bonello L. Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists. Curr Cardiol Rep 2011, 29.
429. Tsakiris D.A., Scudder L., Hodivala-Dilke K.M., Hynes R.O., Coller B.S. Hemostasis in the Mouse (Mus musculus): a Review. Thromb and Haemostas 1999, 81(2):177-188.
430. Reilly M.P., McKenzie S.E. Insights from mouse models of heparin-induced thrombocytopenia and thrombosis. Curr Opin Hematol 2002, 9(5):395-400.
431. McKenzie S.E. Humanized mouse models of FcR clearance in immune platelet disorders. Blood Rev 2002, 16(1):3-5.
432. Degen J.L. Genetic interactions between the coagulation and fibrinolytic systems. Thromb Haemost 2001, 86(1):130-137.
433. Nurden A., Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost 2011, 9(Suppl 1):76-91.
434. Jagadeeswaran P., Sheehan J.P., Craig F.E., Troyer D. Identification and characterization of zebrafish thrombocytes. Br J Haematol 1999, 107(4):731-738.
435. Albers C.A., Cvejic A., Favier R., Bouwmans E.E., Alessi M.C., Bertone P., et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet 2011, 43(8):735-737.
436. Goodall A.H., Burns P., Salles I., Macaulay I.C., Jones C.I., Ardissino D., et al. Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood 2010, 116(22):4646-4656.
437. Carmeliet P., Moons L., Collen D. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res 1998, 39(1):8-33.
438. Italiano J.E., Lecine P., Shivdasani R.A., Hartwig J.H. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 1999, 147(6):1299-1312.
439. Junt T., Schulze H., Chen Z., Massberg S., Goerge T., Krueger A., et al. Dynamic visualization of thrombopoiesis within bone marrow. Science 2007, 317(5845):1767-1770.
440. Takeda M., Yamashita T., Shinohara M., Sasaki N., Tawa H., Nakajima K., et al. Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging. Int J Cardiovasc Imaging 2011.
441. Klink A., Lancelot E., Ballet S., Vucic E., Fabre J.E., Gonzalez W., et al. Magnetic resonance molecular imaging of thrombosis in an arachidonic acid mouse model using an activated platelet targeted probe. Arterioscler Thromb Vasc Biol 2010, 30(3):403-410.
442. Rouzet F., Sarda-Mantel L., Michel J.B., Le G.D. Molecular imaging of platelet activation in thrombus. J Nucl Cardiol 2009, 16(2):277-286.
443. Ni H., Denis C.V., Subbarao S., Degen J.L., Sato T.N., Hynes R.O., et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000, 106(3):385-392.
444. Minamitani H., Tsukada K., Sekizuka E., Oshio C. Optical bioimaging: from living tissue to a single molecule: imaging and functional analysis of blood flow in organic microcirculation. J Pharmacol Sci 2003, 93(3):227-233.
445. Celi A., Merrill-Skoloff G., Gross P., Falati S., Sim D.S., Flaumenhaft R., et al. Thrombus formation: direct real-time observation and digital analysis of thrombus assembly in a living mouse by confocal and widefield intravital microscopy. J Thromb Haemost 2003, 1(1):60-68.
446. Koike Y., Tanaka K., Okugawa Y., Morimoto Y., Toiyama Y., Uchida K., et al. In vivo real-time two-photon microscopic imaging of platelet aggregation induced by selective laser irradiation to the endothelium created in the beta-actin-green fluorescent protein transgenic mice. J Thromb Thrombolysis 2011, 32(2):138-145.
447. Bellido-Martin L., Chen V., Jasuja R., Furie B., Furie B.C. Imaging fibrin formation and platelet and endothelial cell activation in vivo. Thromb Haemost 2011, 105(5):776-782.
448. Baserga A. The hematologic work of Giulio Bizzozero. Sci Med Ital 1958, 7(1):45-63.